231 related articles for article (PubMed ID: 18223288)
21. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M
Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572
[TBL] [Abstract][Full Text] [Related]
22. Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma.
Leo E; Scheuer L; Schmidt-Wolf IG; Kerowgan M; Schmitt C; Leo A; Baumbach T; Kraemer A; Mey U; Benner A; Parwaresch R; Ho AD
Eur J Haematol; 2004 Oct; 73(4):251-7. PubMed ID: 15347311
[TBL] [Abstract][Full Text] [Related]
23. Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.
Janikova A; Koristek Z; Vinklarkova J; Pavlik T; Sticha M; Navratil M; Kral Z; Vasova I; Mayer J
Exp Hematol; 2009 Nov; 37(11):1266-73. PubMed ID: 19654036
[TBL] [Abstract][Full Text] [Related]
24. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.
Tam CS; Wolf MM; Westerman D; Januszewicz EH; Prince HM; Seymour JF
Clin Lymphoma Myeloma; 2005 Sep; 6(2):136-9. PubMed ID: 16231852
[TBL] [Abstract][Full Text] [Related]
25. [Evaluation of the clinical effectivity and toxicity of the FDN regimen (fludarabin, mitoxantron, dexamethason) in patients with follicular lymphoma].
Oborilová A; Mayer J; Korístek Z; Hofmanová Z; Vásová I; Navrátil M; Vinklárková J; Muzikárová M; Klabusay M; Matuska M
Cas Lek Cesk; 2004; 143(10):685-90. PubMed ID: 15584619
[TBL] [Abstract][Full Text] [Related]
26. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
[TBL] [Abstract][Full Text] [Related]
27. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
Tsimberidou AM; Keating MJ; Giles FJ; Wierda WG; Ferrajoli A; Lerner S; Beran M; Andreeff M; Kantarjian HM; O'Brien S
Cancer; 2004 Jun; 100(12):2583-91. PubMed ID: 15197800
[TBL] [Abstract][Full Text] [Related]
28. Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas.
Domingo-Domènech E; González-Barca E; Estany C; Sureda A; Besalduch J; Fernández de Sevilla A
Haematologica; 2002 Nov; 87(11):1229-30. PubMed ID: 12414357
[TBL] [Abstract][Full Text] [Related]
29. Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
Laurenti L; Tarnani M; De Padua L; Efremov DG; Zini G; Garzia M; Piccirillo N; Chiusolo P; Sorà F; Innocenti I; Sica S; Leone G
Ann Hematol; 2008 Nov; 87(11):891-8. PubMed ID: 18587576
[TBL] [Abstract][Full Text] [Related]
30. Radiotherapy for stage I-III nodal low-grade non-Hodgkin's lymphoma.
Ott OJ; Rödel C; Gramatzki M; Niedobitek G; Sauer R; Grabenbauer GG
Strahlenther Onkol; 2003 Oct; 179(10):694-701. PubMed ID: 14566478
[TBL] [Abstract][Full Text] [Related]
31. Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma.
Santini G; Nati S; Spriano M; Gallamini A; Pierluigi D; Congiu AM; Truini M; Rubagotti A; Chisesi T; Vimercati R; Rossi E; Sertoli MR; Mattei D; Marino G; Gobbi M
Haematologica; 2001 Mar; 86(3):282-6. PubMed ID: 11255275
[TBL] [Abstract][Full Text] [Related]
32. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
Tam CS; Wolf MM; Januszewicz EH; Prince HM; Westerman D; Seymour JF
Cancer; 2004 May; 100(10):2181-9. PubMed ID: 15139062
[TBL] [Abstract][Full Text] [Related]
33. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
[TBL] [Abstract][Full Text] [Related]
34. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.
Forstpointner R; Dreyling M; Repp R; Hermann S; Hänel A; Metzner B; Pott C; Hartmann F; Rothmann F; Rohrberg R; Böck HP; Wandt H; Unterhalt M; Hiddemann W;
Blood; 2004 Nov; 104(10):3064-71. PubMed ID: 15284112
[TBL] [Abstract][Full Text] [Related]
35. Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Ferrario A; Merli F; Luminari S; Stelitano C; Mannina D; Russo M; Mazza P; Marcheselli L; Goldaniga MC; Federico M; Baldini L;
Ann Hematol; 2011 Mar; 90(3):323-30. PubMed ID: 20848104
[TBL] [Abstract][Full Text] [Related]
36. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S
Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969
[TBL] [Abstract][Full Text] [Related]
37. Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia.
Tóthová E; Kafková A; Fricová M; Guman T; Stecová N
Neoplasma; 2003; 50(6):433-7. PubMed ID: 14689065
[TBL] [Abstract][Full Text] [Related]
38. Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma.
Zinzani PL; Stefoni V; Musuraca G; Tani M; Alinari L; Gabriele A; Marchi E; Pileri S; Baccarani M
Cancer; 2004 May; 100(10):2190-4. PubMed ID: 15139063
[TBL] [Abstract][Full Text] [Related]
39. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.
Federico M; Luminari S; Dondi A; Tucci A; Vitolo U; Rigacci L; Di Raimondo F; Carella AM; Pulsoni A; Merli F; Arcaini L; Angrilli F; Stelitano C; Gaidano G; Dell'olio M; Marcheselli L; Franco V; Galimberti S; Sacchi S; Brugiatelli M
J Clin Oncol; 2013 Apr; 31(12):1506-13. PubMed ID: 23530110
[TBL] [Abstract][Full Text] [Related]
40. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]